1. Scrip
  2. >>Archive

Theravance Advances Respiratory Program via Glaxo Partnership

 
• By Mark Ratner

The goal of the deal between Glaxo and Theravance is to pool programs in order to develop a best-in-class long-acting beta agonist. That Glaxo is contributing its most advanced compounds to the program and has agreed to pay royalties even on LABAs it may develop separately validates Theravance's technology. But it also shows how Glaxo is weighing the value of external vs. internal R&D.

A company that's raised $370 million in private money over five years yet has only one press release on its web site sounds more like an old school pharma-style operation than the standard entrepreneurial biotech start-up. Indeed, that's the case with Theravance Inc. (formerly Advanced Medicine), which was founded and is chaired by former Merck & Co. Inc. chairman and CEO Roy Vagelos, MD. That solitary press release was the announcement in January of a collaboration with GlaxoSmithKline PLC to develop a long-acting Beta2 agonist (LABA) for the treatment of respiratory disease such as asthma and chronic obstructive pulmonary disease (COPD) [See Deal].

Although the deal specifies that the two companies will pool their most advanced LABA candidates, the goal, according to Theravance...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?